无码人妻久久一区二区三区蜜桃_日本高清视频WWW夜色资源_国产AV夜夜欢一区二区三区_深夜爽爽无遮无挡视频,男人扒女人添高潮视频,91手机在线视频,黄页网站男人的天,亚洲se2222在线观看,少妇一级婬片免费放真人,成人欧美一区在线视频在线观看_成人美女黄网站色大免费的_99久久精品一区二区三区_男女猛烈激情XX00免费视频_午夜福利麻豆国产精品_日韩精品一区二区亚洲AV_九九免费精品视频 ,性强烈的老熟女

Recombinant Human IL-17C Protein

來源: 發(fā)布時間:2024-04-18

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.α-凝血酶(α-Thrombin)可以啟動XIII因子和血小板,,或者用作血管收縮劑。Recombinant Human IL-17C Protein,His-Avi Tag

Recombinant Human IL-17C Protein,His-Avi Tag,標(biāo)準(zhǔn)物質(zhì)

ERBB3,又稱HH3(人表皮生長因子受體3),是一種I型膜糖蛋白,是酪氨酸激酶受體ERBC家族的成員,。ERBP家族成員作為表皮生長因子(LU)家族的生長因子的受體,。在ERBP家庭成員中,因?yàn)樗幸粋€缺陷的激酶域。ERBB3在角化細(xì)胞,、黑色素細(xì)胞,、骨骼肌細(xì)胞、成肌細(xì)胞和雪旺細(xì)胞中都有表達(dá),。單體ERbb3是一種低親和性的受體,。ERBB3與ERBB2的異聚反應(yīng)形成高親和性受體復(fù)合物。與此相反,ERBB3同向聚合或異向聚合形成了一個低親和性的結(jié)合物,。因?yàn)镋RBB3含有一個有缺陷的激酶域,ERBB2的激酶域負(fù)責(zé)通過異二重瓣受體啟動酪氨酸磷酸化信號,。研究發(fā)現(xiàn),ERBB3細(xì)胞質(zhì)區(qū)內(nèi)的三個離散氨基酸信號對ERBB2的轉(zhuǎn)導(dǎo)至關(guān)重要。ERBB3的細(xì)胞質(zhì)域也包含6個一致的結(jié)合主題,用于調(diào)節(jié)P85磷酸酶3激酶(PI3K)的HS2領(lǐng)域,以及一個豐富的一致的結(jié)合主題,。ERBB3的細(xì)胞質(zhì)域也包含6個一致的結(jié)合主題,用于調(diào)節(jié)P85磷酸酶3激酶(PI3K)的HS2領(lǐng)域,以及一個豐富的一致的結(jié)合主題,。ERBB3的細(xì)胞質(zhì)域也包含6個一致的結(jié)合主題,用于調(diào)節(jié)P85磷酸酶3激酶(PI3K)的HS2領(lǐng)域,以及一個豐富的一致的結(jié)合主題。表達(dá)區(qū)間及表達(dá)系統(tǒng)重組的人HR3/ERBB3蛋白表達(dá)自于C-端的HK293細(xì)胞和AVI標(biāo)記,。里面有血清20-Thr643,。分子量大約71.6Recombinant Human CD84/SLAMF5(His-Avi Tag)Fractalkine,,指定為CX3CL1,與大多數(shù)其他趨化因子不同,,CX3CL1是I型跨膜(TM)粘附蛋白,。

Recombinant Human IL-17C Protein,His-Avi Tag,標(biāo)準(zhǔn)物質(zhì)

透明質(zhì)酸酶活力單位(Unitdefinition)基于USP透明質(zhì)酸酶參照標(biāo)準(zhǔn),即每分鐘在37℃,,pH5.7的2mL反應(yīng)液中引起OD6000.330個變化定義為一個活力單位,。抑制劑(Inhibitor)Fe2+,F(xiàn)e3+,,Zn2+,,Cu2+,肝素,,金精三羧酸,,硫酸,硝酸,,乙酰化透明質(zhì)酸,,硫酸纖維素酯,,膽汁等結(jié)構(gòu)式(Structure)運(yùn)輸和保存方法冰袋運(yùn)輸。-20℃保存,,兩年有效,。溶液配制溶于0.02MPBS(pH7.0),含77mMNaCl和0.01%BSA,,濃度為1mg/mL?,F(xiàn)配現(xiàn)用。該產(chǎn)品儲存液不穩(wěn)定,,使用時建議現(xiàn)配現(xiàn)用,。為了您的安全和健康,請穿實(shí)驗(yàn)服并戴一次性手套操作,。

糖苷內(nèi)切酶H是一種重組糖苷酶,,能夠?qū)-糖蛋白中的高甘露糖和某些雜合型寡聚糖的殼二糖結(jié)構(gòu)進(jìn)行切割,去除糖蛋白中的N-連接高甘露糖,。糖苷內(nèi)切酶H克隆自褶皺鏈霉菌(Streptomycesplicatus),。并在酵母中重組表達(dá)。本產(chǎn)品帶his標(biāo)簽,,常應(yīng)用于抗體及其相關(guān)蛋白完全去糖基化,。另外,我司還提供其他類型的糖苷酶,,包括糖苷內(nèi)切酶S(Cat#20413ES),,酵母重組表達(dá)的N-糖苷酶F(比活性:750000U/mL),,酵母重組表達(dá)的N-糖苷酶F(比活性:100000U/mL)。儲存條件-15~-25℃保存,,有效期1年,。使用說明變性條件下蛋白質(zhì)去糖基化1)在水中加入1μLBuffer1和目標(biāo)糖蛋白(1-20μg),至終體積10μL,;2)100℃溫度下煮沸10min使其變性,,冰上冷卻,離心10秒,;3)加入2μL的Buffer2,,8μL去離子水,總反應(yīng)體積20μL,;4)加入1-2μL的EndoH,,輕輕混勻。在37℃孵育1-3h,。5)65℃下熱失活10分鐘,。非變性條件下蛋白質(zhì)去糖基化1)在水中加入2μL的Buffer2和目標(biāo)糖蛋白(1-20μg)至終體積為20μL。2)加入2~5μL的EndoH,輕輕混勻,。3)37°C孵育4-24h,。注意:在變性條件下大多數(shù)底物能夠更好的去糖基化,在非變性條件下可能需要增加EndoH的量和延長孵育時間,。N-糖苷酶 F (PNGase F)在酵母中重組表達(dá),,可以裂解由天冬酰胺連接的高甘露糖、雜合和復(fù)雜的寡糖糖蛋白,。

Recombinant Human IL-17C Protein,His-Avi Tag,標(biāo)準(zhǔn)物質(zhì)

Recombinant Biotinylated Human KIR2DL1 Protein,His-Avi Tag性能參數(shù)分子別名(Synonyms)CD158A;CD158Ankat1;cl-42表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)BiotinylatedHumanKIR2DL1ProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsHis22-Arg242.[Accession|P43626]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof27.1kDa.Duetoglycosylation,theproteinmigratesto48-60kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.然而,在肝臟中,,IL-28A誘導(dǎo)的Th1細(xì)胞因子反應(yīng)有助于T細(xì)胞介導(dǎo)的肝炎的炎癥,。Recombinant Human RETN Protein,hFc Tag

透明質(zhì)酸酶,英文名稱Hyaluronidase,,一類能夠降低體內(nèi)透明質(zhì)酸活性的酶的總稱,,結(jié)構(gòu)上由4個相同亞基構(gòu)成。Recombinant Human IL-17C Protein,His-Avi Tag

Recombinant Biotinylated Human AFP (HLA-A*02:03) Protein,His-Avi Tag性能參數(shù)表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)RecombinantBiotinylatedHumanAFP(HLA-A*02:03)ProteinisexpressedfromHEK293withHistagandAvitagattheC-terminal..ItcontainsGly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)andFMNKFIYEIpeptide.[Accession|AAA03604.1(HLA-A*02:03)&P61769(B2M)&FMNKFIYEI]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof50.70kDa.Duetoglycosylation,theproteinmigratesto53-60kDabasedonTris-BisPAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedby>95%asdeterminedbyHPLC制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugetubesbeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.Recombinant Human IL-17C Protein,His-Avi Tag

浦斯瑞(上海)生物醫(yī)藥有限公司匯集了大量的優(yōu)秀人才,,集企業(yè)奇思,創(chuàng)經(jīng)濟(jì)奇跡,,一群有夢想有朝氣的團(tuán)隊(duì)不斷在前進(jìn)的道路上開創(chuàng)新天地,,繪畫新藍(lán)圖,在江蘇省等地區(qū)的化工中始終保持良好的信譽(yù),,信奉著“爭取每一個客戶不容易,,失去每一個用戶很簡單”的理念,,市場是企業(yè)的方向,質(zhì)量是企業(yè)的生命,,在公司有效方針的領(lǐng)導(dǎo)下,,全體上下,團(tuán)結(jié)一致,,共同進(jìn)退,,**協(xié)力把各方面工作做得更好,努力開創(chuàng)工作的新局面,,公司的新高度,,未來浦斯瑞(上海)生物醫(yī)藥供應(yīng)和您一起奔向更美好的未來,即使現(xiàn)在有一點(diǎn)小小的成績,,也不足以驕傲,,過去的種種都已成為昨日我們只有總結(jié)經(jīng)驗(yàn),才能繼續(xù)上路,,讓我們一起點(diǎn)燃新的希望,,放飛新的夢想!